BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 27124680)

  • 1. Survival Analysis of Papillary Thyroid Carcinoma in Relation to Stage and Recurrence Risk: A 20-Year Experience in Pakistan.
    Hassan A; Razi M; Riaz S; Khalid M; Nawaz MK; Syed AA; Bashir H
    Clin Nucl Med; 2016 Aug; 41(8):606-13. PubMed ID: 27124680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
    Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
    Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer.
    Wu MH; Shen WT; Gosnell J; Duh QY
    Head Neck; 2015 Sep; 37(9):1336-43. PubMed ID: 24821456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
    Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
    Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
    J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.
    Chereau N; Dauzier E; Godiris-Petit G; Noullet S; Brocheriou I; Leenhardt L; Buffet C; Menegaux F
    Langenbecks Arch Surg; 2018 May; 403(3):325-332. PubMed ID: 29445865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follicular Thyroid Carcinoma: Disease Response Evaluation Using American Thyroid Association Risk Assessment Guidelines.
    Hassan A; Khalid M; Riaz S; Nawaz MK; Bashir H
    Eur Thyroid J; 2015 Dec; 4(4):260-5. PubMed ID: 26835430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinoma.
    Nam SH; Bae MR; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2018 Dec; 87():158-164. PubMed ID: 30527232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using the American Thyroid Association Risk-Stratification System to Refine and Individualize the American Joint Committee on Cancer Eighth Edition Disease-Specific Survival Estimates in Differentiated Thyroid Cancer.
    Ghaznavi SA; Ganly I; Shaha AR; English C; Wills J; Tuttle RM
    Thyroid; 2018 Oct; 28(10):1293-1300. PubMed ID: 29897011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of BRAF mutation in thyroid papillary cancer.
    Fernandez IJ; Piccin O; Sciascia S; Cavicchi O; Repaci A; Vicennati V; Fiorentino M
    Otolaryngol Head Neck Surg; 2013 Jun; 148(6):919-25. PubMed ID: 23482475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence factors and prevention of complications of pediatric differentiated thyroid cancer.
    Wang C; Chen X; Wei X; Chen F; Wang Y; Shen Z
    Asian J Surg; 2017 Jan; 40(1):55-60. PubMed ID: 27697309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification System.
    Trimboli P; Piccardo A; Signore A; Valabrega S; Barnabei A; Santolamazza G; Di Paolo A; Stati V; Chiefari A; Vottari S; Simmaco M; Ferrarazzo G; Ceriani L; Appetecchia M; Giovanella L
    Thyroid; 2020 May; 30(5):713-719. PubMed ID: 31973653
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment Outcomes and Risk Factors for Recurrence After Definitive Surgery of Locally Invasive Well-Differentiated Papillary Thyroid Carcinoma.
    Kim JW; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
    Thyroid; 2016 Feb; 26(2):262-70. PubMed ID: 26566765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
    Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
    Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management and outcome of recurrent well-differentiated thyroid carcinoma.
    Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the Prognostic Value of the Eighth Edition of the American Joint Committee on Cancer/Tumor Node Metastasis Staging System Between Papillary and Follicular Thyroid Cancer.
    van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
    Thyroid; 2018 Aug; 28(8):976-981. PubMed ID: 29848239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.
    Wang F; Yu X; Shen X; Zhu G; Huang Y; Liu R; Viola D; Elisei R; Puxeddu E; Fugazzola L; Colombo C; Jarzab B; Czarniecka A; Lam AK; Mian C; Vianello F; Yip L; Riesco-Eizaguirre G; Santisteban P; O'Neill CJ; Sywak MS; Clifton-Bligh R; Bendlova B; Sýkorová V; Wang Y; Liu S; Zhao J; Zhao S; Xing M
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3241-3250. PubMed ID: 28582521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of the eight-edition tumor-node-metastasis staging system with N1b for papillary thyroid carcinoma: A multi-institutional cohort study.
    Kim M; Kim HK; Kim HI; Kim EH; Jeon MJ; Yi HS; Kim ES; Kim H; Kim TH; Kim BH; Kim TY; Kang HC; Kim WB; Chung JH; Shong YK; Kim SW; Kim WG
    Oral Oncol; 2018 Nov; 86():48-52. PubMed ID: 30409319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does microscopically involved margin increase disease recurrence after curative surgery in papillary thyroid carcinoma?
    Lang BH; Shek TW; Wan KY
    J Surg Oncol; 2016 May; 113(6):635-9. PubMed ID: 26843438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk-adapted management of papillary thyroid carcinoma according to our own risk group classification system: is thyroid lobectomy the treatment of choice for low-risk patients?
    Ebina A; Sugitani I; Fujimoto Y; Yamada K
    Surgery; 2014 Dec; 156(6):1579-88; discussion 1588-9. PubMed ID: 25262223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.